{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:03:13Z","timestamp":1785330193628,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81360501"],"award-info":[{"award-number":["81360501"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470006"],"award-info":[{"award-number":["81470006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.lfs.2018.09.040","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T04:47:02Z","timestamp":1537591622000},"page":"224-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition"],"prefix":"10.1016","volume":"211","author":[{"given":"Danna","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunlin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0966-1289","authenticated-orcid":false,"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2018.09.040_bb0005","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2018.09.040_bb0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2018.09.040_bb0015","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2018.09.040_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/187152909787581363","article-title":"Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem","volume":"9","author":"Breccia","year":"2009","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"10.1016\/j.lfs.2018.09.040_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2018.09.040_bb0030","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","article-title":"Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias","volume":"22","author":"Shah","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2018.09.040_bb0035","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2018.09.040_bb0040","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cas.12965","article-title":"Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells","volume":"107","author":"Matsuda","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lfs.2018.09.040_bb0045","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2018.09.040_bb0050","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2018.09.040_bb0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2018.09.040_bb0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/epi.3.1.5736","article-title":"HDACs and HDAC inhibitors in colon cancer","volume":"3","author":"Mariadason","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.lfs.2018.09.040_bb0065","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0959-8049(03)00072-8","article-title":"Histone acetylation-mediated regulation of genes in leukaemic cells","volume":"39","author":"Chambers","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2018.09.040_bb0070","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.lfs.2018.09.040_bb0075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2018.09.040_bb0080","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.lfs.2018.09.040_bb0085","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/leu.2012.342","article-title":"Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia","volume":"27","author":"Mims","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.lfs.2018.09.040_bb0090","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cncr.21725","article-title":"Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells","volume":"106","author":"Morotti","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2018.09.040_bb0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2018.09.040_bb0100","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.7150\/thno.16139","article-title":"Depletion of gamma-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with Imatinib","volume":"6","author":"Jin","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2018.09.040_bb0105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.canlet.2014.10.033","article-title":"Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1","volume":"356","author":"Wang","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lfs.2018.09.040_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010941","article-title":"The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo","volume":"5","author":"Lucas","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.09.040_bb0115","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ijc.25660","article-title":"The novel histone deacetylase inhibitor, AR-42, inhibits gp130\/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells","volume":"129","author":"Zhang","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lfs.2018.09.040_bb0120","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1080\/10428194.2017.1298751","article-title":"A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas","volume":"58","author":"Sborov","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lfs.2018.09.040_bb0125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.juro.2015.02.2918","article-title":"Synergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder Cancer","volume":"194","author":"Li","year":"2015","journal-title":"J. Urol."},{"key":"10.1016\/j.lfs.2018.09.040_bb0130","first-page":"1967","article-title":"Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU","volume":"16","author":"Zhou","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lfs.2018.09.040_bb0135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/onc.2012.83","article-title":"SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2018.09.040_bb0140","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.exphem.2016.02.007","article-title":"Regain control of p53: targeting leukemia stem cells by isoform-specific HDAC inhibition","volume":"44","author":"Kuo","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.lfs.2018.09.040_bb0145","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/emboj.2010.136","article-title":"Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis","volume":"29","author":"Wilting","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.lfs.2018.09.040_bb0150","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-11-0046","article-title":"Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma","volume":"71","author":"Ramsey","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2018.09.040_bb0155","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.leukres.2010.01.030","article-title":"Bcr\u2013Abl-independent mechanism of resistance to imatinib in K562 cells: induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs)","volume":"34","author":"Kalle","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.lfs.2018.09.040_bb0160","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2018.09.040_bb0165","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1007\/s00432-016-2229-x","article-title":"Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells","volume":"142","author":"Mahendrarajah","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lfs.2018.09.040_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exphem.2009.10.005","article-title":"Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib","volume":"38","author":"Mor-Tzuntz","year":"2010","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.lfs.2018.09.040_bb0175","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/pros.23318","article-title":"The effect of a histone deacetylase inhibitor (AR-42) on canine prostate cancer growth and metastasis","volume":"77","author":"Elshafae","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.lfs.2018.09.040_bb0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejmech.2017.07.031","article-title":"Heme oxygenase-1: a new druggable target in the management of chronic and acute myeloid leukemia","volume":"142","author":"Salerno","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.lfs.2018.09.040_bb0185","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lfs.2018.09.040_bb0190","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.lfs.2018.09.040_bb0195","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev."},{"key":"10.1016\/j.lfs.2018.09.040_bb0200","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-12-2799","article-title":"PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR\/ABL+ leukemia cells in vitro and in vivo","volume":"19","author":"Dasmahapatra","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2018.09.040_bb0205","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.2165\/11596690-000000000-00000","article-title":"Epigenetic-based therapies in cancer: progress to date","volume":"71","author":"Song","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2018.09.040_bb0210","first-page":"203","article-title":"The role of HDACs as leukemia therapy targets using HDI","volume":"9","author":"Ahmadzadeh","year":"2015","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.lfs.2018.09.040_bb0215","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood-2013-01-451781","article-title":"Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia","volume":"121","author":"Abdel-Wahab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2018.09.040_bb0220","doi-asserted-by":"crossref","first-page":"e0169128","DOI":"10.1371\/journal.pone.0169128","article-title":"Selective inhibitors of histone deacetylases 1 and 2 synergize with azacitidine in acute myeloid leukemia","volume":"12","author":"Min","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.09.040_bb0225","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1158\/1078-0432.CCR-06-0429","article-title":"Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer","volume":"12","author":"Kulp","year":"2006","journal-title":"Clin. Cancer Res."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320518305927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320518305927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T08:21:00Z","timestamp":1538468460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320518305927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":45,"alternative-id":["S0024320518305927"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2018.09.040","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2018.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}